The European Commission expanded the coverage of Pfizer Inc.'s Nimenrix to include the use of the antibacterial vaccine in infants as young as six weeks.

Nimenrix is now the only vaccine of its kind that can be administered in European patients from six weeks of age without an upper age limit.